Advanced search
Publication Cover
Expert Opinion on Drug Safety Volume 13, 2014 - Issue 7
Submit an article Journal homepage
584
Views
23
CrossRef citations to date
0
Altmetric
Drug Safety Evaluations

Safety evaluation of ruxolitinib for treating myelofibrosis

Sofia GalliGuy’s and St Thomas’ NHS Foundation Trust, London, UK
, MB BCh MRCP,
Donal McLornanGuy’s and St Thomas’ NHS Foundation Trust, London, UK
, MB BCh MRCP PhD FRCPath &
Claire HarrisonGuy’s and St Thomas’ NHS Foundation Trust, Guy’s Hospital, Great Maze Pond, London SE1 9RT, UK+44 2071882742; +44 2071882728; [email protected]
, DM FRCP FRCPath
Pages 967-976 | Published online: 04 Jun 2014

Citations (23)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Dong Won Baek, Hee Jeong Cho, Jung Min Lee, Juhyung Kim, Joon Ho Moon & Sang Kyun Sohn. (2022) Light and shade of ruxolitinib: positive role of early treatment with ruxolitinib and ruxolitinib withdrawal syndrome in patients with myelofibrosis. Expert Review of Hematology 15:7, pages 573-581.
Read now
Korn Triyangkulsri & Poonkiat Suchonwanit. (2018) Role of janus kinase inhibitors in the treatment of alopecia areata. Drug Design, Development and Therapy 12, pages 2323-2335.
Read now

Articles from other publishers (21)

Clement Chung. (2023) Current therapies for classic myeloproliferative neoplasms: A focus on pathophysiology and supportive care. American Journal of Health-System Pharmacy 80:22, pages 1624-1636.
Crossref
T. Y. J. Appeldoorn, T. H. Oude Munnink, L. M. Morsink, M. N. Lub-de Hooge & D. J. Touw. (2023) Pharmacokinetics and Pharmacodynamics of Ruxolitinib: A Review. Clinical Pharmacokinetics 62:4, pages 559-571.
Crossref
Shahnawaz D. Jadeja, Ankit H. Bharti, Mitesh Dwivedi, Jayvadan Vaishnav, Jay Mayatra, Ashwin Kotnis, Amina R. Gani, Naresh C. Laddha & Rasheedunnisa Begum. 2023. Translational Autoimmunity. Translational Autoimmunity 49 77 .
Domenico Penna. (2021) New Horizons in Myeloproliferative Neoplasms Treatment: A Review of Current and Future Therapeutic Options. Medicina 57:11, pages 1181.
Crossref
Sandhya Shanthosh Kumar, Vignesh Krishnan Nagesh, Keerthana P Sivakolundu, Bahadur Ali & Ibrahim Sange. (2021) Posterior Reversible Encephalopathy Syndrome (PRES) in a Patient With Primary Myelofibrosis on Ruxolitinib. Cureus.
Crossref
Fiorenza Barraco, Richard Greil, Raoul Herbrecht, Burkhard Schmidt, Andreas Reiter, Wolfgang Willenbacher, Reinier Raymakers, Rüdiger Liersch, Monika Wroclawska, Robert Pack, Karin Burock, Divyadeep Karumanchi & Heinz Gisslinger. (2020) Real‐world non‐interventional long‐term post‐authorisation safety study of ruxolitinib in myelofibrosis. British Journal of Haematology 191:5, pages 764-774.
Crossref
Prithviraj Bose & Srdan Verstovsek. (2020) JAK Inhibition for the Treatment of Myelofibrosis: Limitations and Future Perspectives. HemaSphere 4:4, pages e424.
Crossref
Francesca Palandri, Massimo Breccia, Massimiliano Bonifacio, Nicola Polverelli, Elena M. Elli, Giulia Benevolo, Mario Tiribelli, Elisabetta Abruzzese, Alessandra Iurlo, Florian H. Heidel, Micaela Bergamaschi, Alessia Tieghi, Monica Crugnola, Francesco Cavazzini, Gianni Binotto, Alessandro Isidori, Nicola Sgherza, Costanza Bosi, Bruno Martino, Roberto Latagliata, Giuseppe Auteri, Luigi Scaffidi, Davide Griguolo, Malgorzata Trawinska, Daniele Cattaneo, Lucia Catani, Mauro Krampera, Roberto M. Lemoli, Antonio Cuneo, Gianpietro Semenzato, Robin Foà, Francesco Di Raimondo, Daniela Bartoletti, Michele Cavo, Giuseppe A. Palumbo & Nicola Vianelli. (2019) Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis. Cancer 126:6, pages 1243-1252.
Crossref
Marissa A. Zarakas, Jigar V. Desai, Georgios Chamilos & Michail S. Lionakis. (2019) Fungal Infections with Ibrutinib and Other Small-Molecule Kinase Inhibitors. Current Fungal Infection Reports 13:3, pages 86-98.
Crossref
Douglas Tremblay, Juan Putra, Alexander Vogel, Adam Winters, Ronald Hoffman, Thomas D. Schiano, Maria Isabel Fiel & John O. Mascarenhas. (2019) The Implications of Liver Biopsy Results in Patients with Myeloproliferative Neoplasms Being Treated with Ruxolitinib. Case Reports in Hematology 2019, pages 1-3.
Crossref
Arief Gunawan, Patrick Harrington, Natalia Garcia-Curto, Donal McLornan, Deepti Radia & Claire Harrison. (2018) Ruxolitinib for the Treatment of Essential Thrombocythemia. HemaSphere 2:4, pages e56.
Crossref
Natalia Curto-Garcia & Claire N Harrison. (2018) An updated review of the JAK1/2 inhibitor (ruxolitinib) in the Philadelphia-negative myeloproliferative neoplasms . Future Oncology 14:2, pages 137-150.
Crossref
Samah Alimam & Claire Harrison. (2017) Experience with ruxolitinib in the treatment of polycythaemia vera. Therapeutic Advances in Hematology 8:4, pages 139-151.
Crossref
M Marchetti, G Barosi, F Cervantes, G Birgegård, M Griesshammer, C Harrison, R Hehlmann, J-J Kiladjian, N Kröger, M F McMullin, F Passamonti, A Vannucchi & T Barbui. (2016) Which patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendations. Leukemia 31:4, pages 882-888.
Crossref
William Damsky & Brett A. King. (2017) JAK inhibitors in dermatology: The promise of a new drug class. Journal of the American Academy of Dermatology 76:4, pages 736-744.
Crossref
Mehdi Rashighi & John E. Harris. (2017) Vitiligo Pathogenesis and Emerging Treatments. Dermatologic Clinics 35:2, pages 257-265.
Crossref
Preetesh Jain, Michael Keating, Sarah Renner, Charles Cleeland, Huang Xuelin, Graciela Nogueras Gonzalez, David Harris, Ping Li, Zhiming Liu, Ivo Veletic, Uri Rozovski, Nitin Jain, Phillip Thompson, Prithviraj Bose, Courtney DiNardo, Alessandra Ferrajoli, Susan O'Brien, Jan Burger, William Wierda, Srdan Verstovsek, Hagop Kantarjian & Zeev Estrov. (2017) Ruxolitinib for symptom control in patients with chronic lymphocytic leukaemia: a single-group, phase 2 trial. The Lancet Haematology 4:2, pages e67-e74.
Crossref
Giuseppe Tridente. 2017. Adverse Events and Oncotargeted Kinase Inhibitors. Adverse Events and Oncotargeted Kinase Inhibitors 375 393 .
Franck Debeurme, Catherine Lacout, Claudine Moratal, Rebecca G. Bagley, William Vainchenker, Francisco Adrian & Jean‐Luc Villeval. (2015) JAK2 inhibition has different therapeutic effects according to myeloproliferative neoplasm development in mice. Journal of Cellular and Molecular Medicine 19:11, pages 2564-2574.
Crossref
Srdan Verstovsek & Rami S Komrokji. (2015) A comprehensive review of pacritinib in myelofibrosis. Future Oncology 11:20, pages 2819-2830.
Crossref
Greg L. Plosker. (2015) Ruxolitinib: A Review of Its Use in Patients with Myelofibrosis. Drugs 75:3, pages 297-308.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.